CONTINGENT VALUE RIGHT AGREEMENTContingent Value Right Agreement • October 23rd, 2024 • Lumos Pharma, Inc. • Pharmaceutical preparations • Delaware
This Contingent Value Right Agreement, dated as of [●], 2024 (this “Agreement”), is entered into by and DPV Parent, Inc., a Delaware corporation (“Parent”), and [RIGHTS AGENT], a [●], as Rights Agent (the “Rights Agent”).
TENDER AND SUPPORT AGREEMENTTender and Support Agreement • October 23rd, 2024 • Lumos Pharma, Inc. • Pharmaceutical preparations • Delaware
This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of October 22, 2024, is entered into by and among DPV Parent, Inc., a Delaware corporation (“Parent”), DPV MergerSub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”), and the Person or Persons set forth on Schedule A hereto (“Stockholder”). All capitalized terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).
AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • October 23rd, 2024 • Lumos Pharma, Inc. • Pharmaceutical preparations • Delaware
AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of October 22, 2024, among DPV Parent, Inc., a Delaware corporation (“Parent”), DPV MergerSub, Inc., a Delaware corporation and a wholly-owned Subsidiary of Parent (“Merger Sub”), Lumos Pharma, Inc., a Delaware corporation (the “Company”), and, solely for the purposes of Section 9.17, Double Point Ventures LLC, a Delaware limited liability company (“DPV”).
CLINICAL TRIAL FUNDING AGREEMENTClinical Trial Funding Agreement • October 23rd, 2024 • Lumos Pharma, Inc. • Pharmaceutical preparations • Delaware
This Clinical Trial Funding Agreement (this “Agreement”) is made as of October 22, 2024 (the “Effective Date”) by and between Double Point Ventures LLC, a Delaware limited liability company (“Lender”) and Lumos Pharma, Inc., a Delaware corporation (“Borrower”).
